Wait Before buying - check if the support level will not be broken before buying, otherwise hold
Fundamental Analysis
Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available.
A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021.
As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.
Fundamental Analysis
Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available.
A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021.
As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。